Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

A dual-action approach to preventing hepatocellular carcinoma

21

Jan 2026

A dual-action approach to preventing hepatocellular carcinoma

Hepatocellular carcinoma is one of the leading causes of cancer-related death worldwide, largely due to its high rate of recurrence after surgery. Even after complete tumor removal, microscopic residual disease and early dissemination frequently lead to relapse within the first two years.

Tracing the decline in American heart disease mortality

21

Jan 2026

Tracing the decline in American heart disease mortality

Following a five-year upward trend likely impacted by the COVID pandemic, the number of heart disease and stroke deaths has declined, yet, heart disease and stroke still kill more people in the U.S. each year than any other cause, according to data reported in the 2026 Heart Disease and Stroke Statistics: A Report of U.S. and Global Data From the American Heart Association.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.